Narcolepsy Type 1 Clinical Trials

11 recruiting

Narcolepsy Type 1 Trials at a Glance

14 actively recruiting trials for narcolepsy type 1 are listed on ClinicalTrialsFinder across 6 cities in 15 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Cincinnati, Austin, and Atlanta. Lead sponsors running narcolepsy type 1 studies include Takeda, Alkermes, Inc., and Centessa Pharmaceuticals (UK) Limited.

Browse narcolepsy type 1 trials by phase

Treatments under study

About Narcolepsy Type 1 Clinical Trials

Looking for clinical trials for Narcolepsy Type 1? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Narcolepsy Type 1 trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Narcolepsy Type 1 clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Not Applicable

Pain Assessment in Patients With Idiopathic Rapid Eye Movement (REM) Sleep Behaviour Disorder

REM Sleep Behavior Disorder (iRBD)Narcolepsy Type 1
University Hospital, Toulouse24 enrolled1 locationNCT07365566
Recruiting
Phase 2

A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

Idiopathic HypersomniaNarcolepsy Type 1Narcolepsy Type 2
Centessa Pharmaceuticals (UK) Limited248 enrolled37 locationsNCT06752668
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

Narcolepsy Type 1
Alkermes, Inc.150 enrolled3 locationsNCT07455383
Recruiting
Phase 2

A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

Idiopathic HypersomniaNarcolepsy Type 1Narcolepsy Type 2
Centessa Pharmaceuticals (UK) Limited90 enrolled24 locationsNCT07096674
Recruiting
Phase 3

A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy

Narcolepsy Type 1 (NT1)Narcolepsy With Cataplexy
Takeda88 enrolled7 locationsNCT07363720
Recruiting
Phase 2Phase 3

A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

Narcolepsy Type 1
Takeda500 enrolled52 locationsNCT05816382
Recruiting

Epidemiology of Narcolepsy Type 1 and Type 2 in Spain

Narcolepsy Type 1Narcolepsy Type 2
Takeda100 enrolled10 locationsNCT07299097
Recruiting
Phase 2Phase 3

A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia

Idiopathic HypersomniaNarcolepsy Type 1Narcolepsy Type 2
Alkermes, Inc.256 enrolled46 locationsNCT06767683
Recruiting

Bacterial Translocation and Gut Microbiota in Type 1 Narcolepsy Patients Versus a Control Population

Narcolepsy Type 1Bacterial Translocation
Centre Hospitalier Universitaire de Nīmes120 enrolled2 locationsNCT06292598
Recruiting
Phase 2

Extended-release Sodium Oxybate in Children

Narcolepsy Type 1 (NT 1)
Stanford University36 enrolled1 locationNCT06809803
Recruiting
Not Applicable

A Novel Approach to Manage Symptoms of Narcolepsy and Idiopathic Hypersomnia

Idiopathic HypersomniaNarcolepsy Type 1 (NT 1)Narcolepsy Type 2 (NT2)
University of Sydney30 enrolled1 locationNCT07006233
Recruiting
Not Applicable

Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions

Idiopathic HypersomniaNarcolepsy Type 1Hypersomnolence
Hospices Civils de Lyon180 enrolled1 locationNCT06457945
Recruiting
Not Applicable

Deciphering the Interactions Between Food Intake, Sleepiness, and Nighttime Sleep Quality in Patients With Type 1 Narcolepsy and Idiopathic Hypersomnia

Idiopathic HypersomniaNarcolepsy Type 1
Hospices Civils de Lyon60 enrolled2 locationsNCT06484348
Recruiting

Mentalizating in Adults Suffering from Narcolepsy Type 1.

Narcolepsy Type 1
University Hospital, Toulouse60 enrolled1 locationNCT06336057